Risk of Severe Outcomes From COVID-19 in Comorbid Populations in the Omicron Era: A Meta-analysis
Authors: Chapman Akvile , Barouch Dan H. , Lip Gregory Y. H. , Pliakas Triantafyllos , Polverino Eva , Sourij Harald , Abduljawad Sultan 
Published: December 2024

Importance

This is the first meta-analysis to investigate risk of death and hospitalization in individuals with comorbidities, specifically during the Omicron era.

Objective

To assess the risk of mortality and hospitalization from COVID-19 in individuals with comorbidities in comparison with individuals without comorbidities during the Omicron era.

Data Sources

A systematic search of Embase, MEDLINE, PubMed, Europe PMC, Latin American and Caribbean Health Sciences Literature, Cochrane COVID-19 Study Register, and WHO COVID-19 Database was performed to identify studies published between 1 January 2022 and 13 March 2024.

Study Selection

Inclusion criteria were observational studies including people (all ages) with at least 1 of the following comorbidities: cardiovascular/ cerebrovascular disease, chronic lung conditions, diabetes, and obesity. In total, 72 studies were included in the review, of which 68 were meta-analyzed.

Data Extraction and Synthesis

Data were extracted by one reviewer and verified by a second. Studies were synthesized quantitively (meta-analysis) using random-effect models. PRISMA guidelines were followed.

Main Outcomes and Measures

Evaluated outcomes were the risks of death, hospitalization, intensive care unit (ICU) admission, and any combination of these outcomes. Odds ratios, hazard ratios, and rate ratios were extracted; pooled relative risk (RR) and 95% confidence intervals (CI) were calculated.

Results

Minimum numbers of participants per comorbidity across included studies ranged from 328 870 for thrombosis to 13 720 480 for hypertension. Risks of death, hospitalization, and the combined outcome were increased in individuals with cerebrovascular disease, COPD, diabetes, respiratory diseases, heart disease, and heart failure versus those without (pooled RRs ranged from 1.27 [heart disease, hospitalization; 95% CI, 1.17-1.38,P< .001] to 1.78 [heart failure, death: 95% CI, 1.46-2.16,P< .001]). Individuals with diabetes and obesity had increased risk of ICU admission (RR: 1.20; 95% CI: 1.04-1.38,P= .0141 and RR: 1.32; 95% CI: 1.11-1.57,P= .00158, respectively).

Conclusions

During the Omicron era, risk of death and hospitalization from COVID-19 is increased amongst individuals with comorbidities including cerebrovascular/cardiovascular conditions, chronic lung diseases, and diabetes, with the highest risk in those with heart failure. Individuals with diabetes and obesity are at increased risk of ICU admission.

Key Points

Question

What are the risks of severe outcomes from COVID-19 in individuals with comorbidities during the Omicron era?

Findings

This systematic review and meta-analysis found increased risk of mortality and hospitalization among individuals with a range of comorbidities, including cerebrovascular/cardiovascular conditions, chronic lung diseases, and diabetes, with the highest risk in those with heart failure, versus those without. Risk of ICU admission was higher in individuals with obesity and diabetes.

Meaning

This study identified comorbid populations most at risk of severe outcomes from COVID-19. Targeting these populations with public health measures, such as vaccination, may be beneficial.